Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swamy, M. V.
Right arrow Articles by Rao, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swamy, M. V.
Right arrow Articles by Rao, C. V.
[Cancer Research 63, 5239-5242, September 1, 2003]
© 2003 American Association for Cancer Research


Advances in Brief

Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p531

Malisetty V. Swamy2, Christopher R. Herzog2 and Chinthalapally V. Rao3

Chemoprevention Program, Institute For Cancer Prevention, American Health Foundation Cancer Center, Valhalla, New York 10595

Inactivation of the p53 tumor suppressor gene usually involves somatic mutation or binding of viral oncoproteins to the p53 protein. However, several types of malignant and premalignant tissues harbor a genetically wild-type, but transcriptionally inactive, form of p53, often localized in the cytoplasm. Electrophilic prostaglandins (PGs) are known to sequester and inactivate p53 in the cytoplasm, an effect that is likely to occur when cyclooxygenase (COX)-2 levels become elevated during colon carcinogenesis. We determined the localization and expression of p53 in the presence of PGA1 and celecoxib, a selective COX-2 inhibitor in human colon cell lines HCT-116 (wild-type p53) and HT-29 (mutant p53). In the absence of treatment, p53 protein accumulated preferentially in the nucleus in both cell lines. We observed that the total cellular levels of p53 protein increased with exposure time and concentration of PGA1. By contrast, p21 protein levels remained unchanged as a function of time and concentration of PGA1. In the presence of 20 µM PGA1, p53 accumulated preferentially in the cytosol. The nuclear:cytosol ratios of p53 were 31 and 2.1 in the controls and in the presence of PGA1 in HCT-116 cells but were 22 and 4, respectively, in HT-29 cells. Treatment with 50 µM celecoxib for 24 h did not significantly change p53 expression and localization. However, in the presence of 100 µM celecoxib, p53 levels increased in the nucleus. The nuclear:cytosol ratios were then 31 (control) and 60 (100 µM celecoxib) in HCT-116 cells and 22 (control) and 36 (100 µM celecoxib) in HT-29 cells. These results indicate that electrophilic PGs cause wild-type p53 accumulation in the cytosol where it is inactive. Inhibition of COX-2 by celecoxib appears to alleviate this effect on p53 by reducing electrophilic PG synthesis. Thus, COX-2 inhibition of electrophilic PG formation appears to protect p53 tumor suppressor function.




This article has been cited by other articles:


Home page
Cancer Res.Home page
K.-S. Chun, J. K. Akunda, and R. Langenbach
Cyclooxygenase-2 Inhibits UVB-Induced Apoptosis in Mouse Skin by Activating the Prostaglandin E2 Receptors, EP2 and EP4
Cancer Res., March 1, 2007; 67(5): 2015 - 2021.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
H. Tsubochi, N. Sato, M. Hiyama, M. Kaimori, S. Endo, Y. Sohara, and T. Imai
Combined Analysis of Cyclooxygenase-2 Expression With p53 and Ki-67 in Nonsmall Cell Lung Cancer.
Ann. Thorac. Surg., October 1, 2006; 82(4): 1198 - 1204.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H.-Y. Tang, A. Shih, H. J. Cao, F. B. Davis, P. J. Davis, and H.-Y. Lin
Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells.
Mol. Cancer Ther., August 1, 2006; 5(8): 2034 - 2042.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. V. Swamy, J. M.R. Patlolla, V. E. Steele, L. Kopelovich, B. S. Reddy, and C. V. Rao
Chemoprevention of Familial Adenomatous Polyposis by Low Doses of Atorvastatin and Celecoxib Given Individually and in Combination to APCMin Mice.
Cancer Res., July 15, 2006; 66(14): 7370 - 7377.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X.-H. Liu, A. Kirschenbaum, K. Yu, S. Yao, and A. C. Levine
Cyclooxygenase-2 Suppresses Hypoxia-induced Apoptosis via a Combination of Direct and Indirect Inhibition of p53 Activity in a Human Prostate Cancer Cell Line
J. Biol. Chem., February 4, 2005; 280(5): 3817 - 3823.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. H. Schonthal, C. R. Herzog, M. V. Swamy, and C. V. Rao
Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p53. Cancer Res 2003;63:5239-42.
Cancer Res., April 15, 2004; 64(8): 2937 - 2938.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.